CypioTrex 350mg/ml 10ml Vial by Concentrex Labs

Usage

1. PLAN YOUR PHASES BEFORE STARTING: Map out intended blast duration (8–16 weeks), target weekly dose for each phase, and a minimum cruise duration of 8 weeks. Calculate total testosterone required and confirm your 10 ml vial supply covers both phases.
2. DRAW USING CORRECT SYRINGE SIZE: For cruise doses of 100–200 mg (0.29–0.57 ml), a 1 ml luer-lock syringe provides adequate accuracy. For blast doses of 350–700 mg (1.0–2.0 ml), use an appropriate luer-lock barrel. Swab the septum with an alcohol wipe before each draw.
3. WARM THE VIAL IF NEEDED: At 350 mg/ml, solution viscosity can increase at cooler room temperatures. Hold the vial in your palm for 30–60 seconds or briefly place it in warm (not hot) water to reduce viscosity before drawing.
4. ADMINISTER INTRAMUSCULARLY OR SUBCUTANEOUSLY: Glute, vastus lateralis, and deltoid are conventional IM sites. For cruise-phase micro-doses (≤ 0.5 ml), subcutaneous administration in the abdomen or upper glute is a viable alternative tolerated by many users.
5. MONITOR BLOODWORK AT PHASE TRANSITIONS: Request a complete panel — including serum testosterone, haematocrit, LH, FSH, PSA, and lipid profile — before initiating each new blast. Use cruise-phase results to confirm recovery before dose escalation.
6. ADJUST CRUISE DURATION BASED ON DATA, NOT CALENDAR: Extend the cruise phase if haematocrit remains above 52% or lipid markers have not returned to acceptable range. Only re-enter the blast window once bloodwork confirms physiological tolerance.

Warnings

Frequently asked questions

What does a cruise-and-blast protocol involve with testosterone cypionate?

A cruise-and-blast protocol alternates between a supraphysiological blast phase — typically 350–700 mg of testosterone per week — and a maintenance cruise phase at 100–200 mg per week. Testosterone cypionate is the preferred ester for this structure because its 7–9-day release window produces gradual serum curves in both phases, avoiding the hormonal instability associated with short-acting compounds during phase transitions.

How long should the cruise phase last before starting the next blast?

Most experienced practitioners run cruise phases between 8 and 12 weeks, long enough for haematological markers (haematocrit, RBC count) and lipid panels to trend back toward baseline. The exact duration depends on bloodwork results rather than a fixed calendar. Testosterone cypionate's slow ester release means cruise-phase serum levels stabilise within approximately two weeks of reducing the dose, allowing meaningful marker recovery before the next blast begins.

When is the right point to switch from the blast phase back to cruise?

The transition from blast to cruise is typically triggered by a combination of time-based targets (8–16 weeks of elevated dosing) and subjective recovery signals such as cardiovascular strain, sleep quality, and appetite. Many athletes also schedule the switch around a deload training block. With testosterone cypionate, the dose reduction takes effect gradually over 7–10 days due to the ester's depot release, so the serum drop into cruise range is smooth rather than abrupt.

How does the 350mg/ml concentration affect injection volume when using insulin syringes?

At 350 mg/ml, a 100 mg cruise dose requires only 0.29 ml — within the range of a standard 0.5 ml insulin syringe, making shallow subcutaneous administration feasible for cruise-phase injections. A 350 mg blast dose draws exactly 1 ml, which fits a standard 1 ml luer-lock syringe. The high concentration reduces dead-volume waste per draw compared to lower-density formulations, which is particularly relevant across a multi-month cruise-and-blast cycle.

How should the CypioTrex 10ml vial be stored after the first puncture?

After the rubber septum has been first punctured, store the vial at room temperature (15–25 °C), away from direct light and heat sources; refrigeration is not required but prolongs shelf life. The multi-dose septum and preservative system in CypioTrex are validated for repeated puncture across an extended draw schedule. Discard any remaining solution if the oil appears cloudy, discoloured, or shows visible particulate matter, regardless of the stated expiry date. (2) angle_used

Manufacturer

Concentrex Labs' distribution infrastructure is built around the practical realities of the cruise-and-blast user base it primarily serves: athletes who plan 20–30+ week combined blast-and-cruise cycles need reliable, repeatable access to the same product across successive orders. To meet that demand, Concentrex Labs maintains multi-market distribution partnerships that prioritise short order-to-dispatch windows and consistent batch availability — minimising the supply-chain interruptions that force mid-cycle product substitutions. Vials leave the facility only after batch-release documentation is finalised, meaning each unit shipped carries a traceable production record covering HPLC potency results, LAL endotoxin data, and carrier-oil specification compliance. Cold-chain integrity during transit is managed through validated secondary packaging appropriate to the thermal profile of the destination market, preserving solution stability from warehouse to end user.